Rate of combined clinically significant or severe hypoglycemia significantly lower with efsitora versus glargine<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, June 27, 2025 (HealthDay News) — Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among adults with type 2 diabetes, according to a study published online June 25 in the New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.<\/p>\n Julio Rosenstock, M.D., from Velocity Clinical Research at Medical City in Dallas, and colleagues conducted a 52-week, phase 3 trial involving adults with type 2 diabetes who had not previously received insulin. A total of 795 participants were randomly assigned to receive once-weekly efsitora, initiated at 100 U, with dose adjustments made every four weeks as needed, or once-daily insulin glargine, with doses adjusted weekly or more often to reach the same glycemic goals.<\/p>\n The researchers observed a decrease in mean HbA1c from baseline to week 52 from 8.20 to 7.05 percent with efsitora and from 8.28 to 7.08 percent with glargine (least-squares mean change, \u22121.19 and \u22121.16 percentage points, respectively), confirming the noninferiority of efsitora to glargine. Superiority was not achieved (P = 0.68). The rate of combined clinically significant hypoglycemia or severe hypoglycemia was lower with efsitora than glargine (0.50 versus 0.88 events per participant-year of exposure; estimated rate ratio, 0.57). The mean total weekly insulin dose was 289.1 and 332.8 U\/week with efsitora and glargine, respectively, at week 52.<\/p>\n “Once-weekly efsitora administered in a fixed-dose regimen was noninferior to once-daily glargine in reducing glycated hemoglobin levels at 52 weeks,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which is developing efsitora and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n